

EFS

Applicant: Erik Buntinx

Serial No.: 10/803,793

Filed: March 18, 2004

Reply filed October 8, 2010

page 2 of 8

Amendments to the Claims:

Please cancel Claim 49 and 72 without prejudice or disclaimer, amend Claims 50, 55, 92 and 93, and add new Claims 94-108 as set forth below.

1-49. (Canceled)

50. (Currently amended) A pharmaceutical combined preparation comprising:

(a) pipamperone in a dose ranging between 5 to 15 mg ~~of the active ingredient~~,
and

(b) pergolide in a dose ranging between 0.5 and 10 mg ~~of the active ingredient~~,
for use for treating Parkinson Disease.

51-54. (Canceled)

55. (Currently amended) A pharmaceutical combined preparation comprising:

(a) pipamperone in a dose ranging between 5 and 15 mg ~~of the active ingredient~~,
and

(b) levodopa/carbidopa in a dose ranging between 2000 mg/ 200 mg and 100 mg/
10 mg ~~of the active ingredients~~,
for use for treating Parkinson Disease.

56-91. (Canceled)

92. (Currently amended) A pharmaceutical combined preparation comprising

EFS

Applicant: Erik Buntinx

Serial No.: 10/803,793

Filed: March 18, 2004

Reply filed October 8, 2010

page 3 of 8

(a) pipamperone in a dose ranging between 5 and 15 mg ~~of the active ingredient~~,
and

(b) levodopa/carbidopa in a dose ranging between 1500 mg/ 150 mg and 250 mg/
25 mg ~~of the active ingredients~~,
for use for treating Parkinson Disease.

93. (Currently amended) A pharmaceutical combined preparation comprising
(a) pipamperone in a dose ranging between 5 and 15 mg ~~of the active ingredient~~,
and

(b) levodopa/carbidopa in a dose of 500 mg/ 50 mg ~~of the active ingredients~~,
for use for treating Parkinson Disease.

94. (New) The pharmaceutical combined preparation of Claim 50 comprising
pergolide in a dose between 2 and 5 mg.

95. (New) The pharmaceutical combined preparation of Claim 50 comprising
pergolide in a dose of 3 mg.

96. (New) The pharmaceutical combined preparation of Claim 50 comprising
pipamperone in a dose 5 mg.

97. (New) The pharmaceutical combined preparation of Claim 50 comprising
pipamperone in a dose 10 mg.

EFS

Applicant: Erik Buntinx

Serial No.: 10/803,793

Filed: March 18, 2004

Reply filed October 8, 2010

page 4 of 8

98. (New) The pharmaceutical combined preparation of Claim 50 comprising pipamperone in a dose 15 mg.

99. (New) The pharmaceutical combined preparation of Claim 55 comprising pipamperone in a dose 5 mg.

100. (New) The pharmaceutical combined preparation of Claim 55 comprising pipamperone in a dose 10 mg.

101. (New) The pharmaceutical combined preparation of Claim 55 comprising pipamperone in a dose 15 mg.

102. (New) The pharmaceutical combined preparation of Claim 50 formulated for daily administration.

103. (New) The pharmaceutical combined preparation of Claim 55 formulated for daily administration.

104. (New) The pharmaceutical combined preparation of Claim 50 formulated for twice daily administration.

105. (New) The pharmaceutical combined preparation of Claim 50, wherein pipamperone is in the form of a pharmaceutically acceptable salt.

EFS

Applicant: Erik Buntinx

Serial No.: 10/803,793

Filed: March 18, 2004

Reply filed October 8, 2010

page 5 of 8

106. (New) The pharmaceutical combined preparation of Claim 55, wherein pipamperone is in the form of a pharmaceutically acceptable salt.

107. (New) The pharmaceutical combined preparation of Claim 50, wherein pergolide is in the form of a pharmaceutically acceptable salt.

108. (New) The pharmaceutical combined preparation of Claim 55, wherein levodopa and carbidopa are in the form of a pharmaceutically acceptable salt.